<DOC>
	<DOCNO>NCT02767674</DOCNO>
	<brief_summary>The purpose study investigate efficacy safety R-GemOx Versus R-miniCHOP first-line treatment elderly patient Diffuse large B cell lymphoma</brief_summary>
	<brief_title>Trial R-GemOx Versus R-miniCHOP Regimen First-line Treatment Elderly Diffuse Large B Cell Lymphoma</brief_title>
	<detailed_description>Gemcitabine Oxaliplatin ( GemOx ) show effective activity patient relapse diffuse large-cell lymphoma solid tumor . Our Previous study show two-weekly regimen rituximab combine GemOx regimen acheived comparable response rate R-miniCHOP.The investigator therefore design open-label , phase III random trial compare safety efficacy R-Gemox versus R-miniCHOP first-line treatment elderly patient diffuse large B cell lymphoma . Primary Outcome Measures : • overall response rate Secondary Outcome Measures : - progression free survival - overall survival - safety toxicity Enrollment:614 Study Start Date : June 2016 Primary Completion Date : June 2016</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>1 . Histologically confirm diffuse large B cell lymphoma（With exception Primary mediastinal large B cell lymphoma、Primary central nervous system lymphoma、HIVrelated lymphoma ) ; 2 . Newdiagnosed untreated ; 3 . Age old 80 year old 70 year ECOG PS ≥ 2 ; 4 . Ann Arbor stage I stage IV disease ; 5 . Understand voluntarily sign informed consent form , able adhere study visit schedule protocol requirement . 1 . Poor hepatic and/or renal function , define total bilirubin , ALT , AST , Cr two fold upper normal level , unless abnormality relate lymphoma ; 2 . Poor bonemarrow reserve , define neutrophil count le 1.5×10⁹/L platelet count less 100×10⁹/L , unless cause bone marrow infiltration ; 3 . Presence Grade III nervous toxicity two week ; 4 . New York Heart Association class III IV cardiac failure ; Ejection fraction le 50 % ; history follow disease past 6 month : acute coronary syndrome、acute heart failure、severe ventricular arrhythmia 5 . Positive HIV , syphilis , HCV , HBV virus load ( HBV DNA ) &gt; 1×105 copies/ml ; 6 . CNS meningeal involvement ; 7 . Concomitant malignancy aggressive B cell lymphoma need Treat , exception nonmelanoma skin tumour stage 0 ( situ ) cervical carcinoma , history cancer 5 year ; 8 . Concomitant hematologic disease ( leukemia , hemophilia primary myelofibrosis ) investigator unsuitable enrol clinical trial ; 9 . Active severe infectious disease ; 10 . Major surgery within three week ; 11 . Any potential drug abuse , medical , psychological social condition may disturb investigation assessment . 12 . In condition investigator consider ineligible study . 13 . Known sensitivity allergy investigational Product .</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>R-Gemox</keyword>
	<keyword>R-miniCHOP</keyword>
	<keyword>elderly patient diffuse large B cell lymphoma</keyword>
</DOC>